Phase 4 N=18 Pregabalin on Colonic Motor and Sensory Function in Constipation Predominant Irritable Bowel Syndrome
Irritable Bowel Syndrome
Primary: Colonic Compliance — 18.96; 16.86; 15.99; 15.75 mm Hg
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=50 The Efficacy of PX0612 In The Treatment Of Irritable Bowel Syndrome
Irritable Bowel Syndrome With Diarrhea
Primary: Change in the Bowel Movements (Stool Frequency) Between the 'Intervention' Group and the 'Placebo' Group Over the Study Period. — .46; .21 bowel movements/day
Phase 2 N=186 A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)
Constipation Predominant Irritable Bowel Syndrome
Primary: Complete Spontaneous Bowel Movement (CSBM) Frequency Change From Baseline — 1.01; 1.50; 1.54; 1.57 number of bowel movements/week
N/A N=52 Effects of Lubiprostone on Gastrointestinal Transit & pH in Irritable Bowel Syndrome (IBS) With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Change in Gastric Emptying Time, Small Bowel Transit Time, Colon Transit Time and Whole Gut Transit Time From Baseline — 5.49; 6.52; -0.16; 0.2 hours
Phase 2 N=428 The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
Irritable Bowel Syndrome Characterized by Constipation
Primary: Change From Baseline in Weekly CSBMs Frequency Over the 12-Week Treatment Period (mITT Population) — 1.28; 2.12; 2.74; 2.44 CSBMs per week
Phase 4 N=74 A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
Irritable Bowel Syndrome
Primary: Change in Mean Daily Abdominal Pain — 5.2; 5.3; 3.9; 3.8 score on a scale — p=0.78
N/A N=4 Effect of Lubiprostone on Small Bowel Contractions in Female Patients With Constipation Irritable Bowel Syndrome (C-IBS)
Constipation-predominant Irritable Bowel Syndrome
Primary: A Change in Length of Spread of Antegrade Contractions After Placebo.
Phase 3 N=803 Trial of Linaclotide Administered to Patients With Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome Characterized by Constipation
Primary: Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks — 20; 49; 375; 356 Participants — p=0.0004
N/A N=17 Effects of a Very Low Carbohydrate Diet on Symptoms of Irritable Bowel Syndrome (IBS)
Diarrhea Predominant Irritable Bowel Syndrome
Primary: Number of Subjects Reporting "Adequate Relief" From IBS Symptoms for the Previous Week. Adequate Relief Was a "True/False" Item. — 13 Participants
Phase 2 N=46 Effects of ROSE-010 on GI Transit in Constipation Predominant Irritable Bowel Syndrome (C-IBS) Patients
Irritable Bowel Syndrome Constipation Predominant
Primary: Colonic Transit, Colonic Geometric Center at 24 Hours — 2.39; 2.37; 2.02; 1.76 units on a scale
Phase 3 N=590 Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome With Constipation
Primary: Overall Responder Rate — 13.8; 7.8 percentage of participants — p=0.029
Phase 3 N=581 Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation
Irritable Bowel Syndrome · Constipation
Primary: Overall Responder Status — 12.1; 5.7 percentage of participants — p=0.023
N/A N=40 The Effect of CSP01 on Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation
Constipation · Chronic Idiopathic Constipation · Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in Colonic Transit Time (CTT) — -727; -15; 366 minutes
Phase 2 N=565 Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With…
N/A N=37 Neomycin and Rifaximin Plus Neomycin in Treating Methane Positive Constipation Predominant Irritable Bowel Syndrome
Constipation-predominant Irritable Bowel Syndrome
Primary: Severity of Constipation in Each Arm at Week 1 After Completion of Therapy — 61.2; 28.6 units on a scale
Phase 3 N=1,054 The Plecanatide Irritable Bowel Syndrome With Constipation Study (IBS-C)
Irritable Bowel Syndrome Characterized by Constipation
Primary: Number of Overall Responders - ITT Population — 63; 106; 103 Participants
Phase 3 N=623 Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
Non-Constipation Irritable Bowel Syndrome
Primary: Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6). — 31.2…
Phase 3 N=535 12-Week Efficacy and Safety Study of Ibodutant in Women With Irritable Bowel Syndrome With Diarrhea (IBS-D)
Irritable Bowel Syndrome With Diarrhea
Primary: Weekly Response for Abdominal Pain Intensity AND Stool Consistency Over 12 Weeks of Treatment in at Least 50% of the Weeks of Treatment (6 Out of 12 Weeks). — 35.7; 34.7…
Phase 3 N=614 A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome Characterized by Constipation
Primary: Overall Change From Baseline in Abdominal Score (Abdominal Bloating, Abdominal Discomfort, and Abdominal Pain) Throughout the Treatment Period — -1.182; -1.898 score on…
Phase 3 N=637 Rifaximin 3 Times/Day (TID) for Non-Constipation Irritable Bowel Syndrome (IBS)
Non-Constipation Irritable Bowel Syndrome
Primary: Proportion of Subjects Who Had Adequate Relief of Global IBS Symptoms for at Least 2 of the 4 Weeks During the Primary Evaluation Period (ie, Weeks 3 Through 6). — 32.2…
Phase 3 N=1,135 Second Plecanatide Study In Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome Characterized by Constipation
Primary: Number of Overall Responders - ITT Population — 54; 81; 91 Participants
Phase 3 N=356 The Efficacy of AZD1722 in Constipation Predominant Irritable Bowel Syndrome (IBS-C)
Constipation Predominant Irritable Bowel Syndrome
Primary: Percent Complete Spontaneous Bowel Movement Responders vs Placebo — 35; 38; 51; 30 Participants — p=<0.001
Phase 3 N=839 A Phase 3, International, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Efficacy and Safety Trial of Linaclotide Administered Orally for 12 Weeks to Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome With Constipation (IBS-C)
Primary: 12-week Abdominal Pain/Abdominal Discomfort Weekly Responder — 250; 206 Participants — p=0.0010
Phase 2 N=7 Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)
Irritable Bowel Syndrome
Primary: Changes in GIS Scores Between Baseline and After a 12 Week Intervention With Mesalamine or Placebo — 2.72; 2.22 units on a scale — p=.001
Phase 4 N=25 Effects of Lubiprostone on Small Bowel and Colonic Bacteria: A Correlation Study With Segmental and Whole Gut Transit
Constipation
Primary: Presence of Small Intestinal Bacterial Overgrowth — 8; 9 Participants — p=0.75
Phase 2 N=532 Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome With Constipation
Primary: Change From Baseline in Weekly Abdominal Pain Score Over the 12-Week Treatment Period: DR1 or IR vs. Placebo — -1.370; -1.938; -1.667; -1.656 score on a scale — p=0.0839
Phase 3 N=805 Trial of Linaclotide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)
Irritable Bowel Syndrome With Constipation
Primary: Abdominal Pain and Complete Spontaneous Bowel Movement (APC) Responder, 9 Out of 12 Weeks — 12; 51 participants — p=<0.0001
N/A N=39 Biomarkers for Intestinal Permeability in Patients With Constipation
Intestinal Diseases · Irritable Bowel Syndrome · Constipation
Primary: Lactulose:C13 Mannitol Excretion Ratio 8-24hrs. — 0.01; 0.02 Ratio — p=0.87
Phase 3 N=224 B. Lactis HN019 for Functional Constipation
Constipation
Primary: Whole Gut Transit Time
N/A N=31 Effect of Tai Chi as Treatment for IBS-C
Irritable Bowel Syndrome With Constipation
Primary: IBS Symptom Severity Score at 12 Weeks — 184.7 score on a scale